Modified MACOP-B chemotherapy for intermediate and high grade non Hodgkins lymphomas

Area of Science:

• Oncology
• Hematology
• Clinical Trials

Background:

• The MACOP-B (methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisolone, and bleomycin) regimen is a standard treatment for Non-Hodgkin Lymphoma.
• Previous studies have reported varying efficacy of the MACOP-B regimen.
• Assessing outpatient administration feasibility and confirming efficacy in a specific population is crucial.

Purpose of the Study:

• To evaluate the feasibility of administering the MACOP-B chemotherapy regimen on an outpatient basis.
• To confirm the efficacy of the MACOP-B regimen in treating intermediate- and high-grade lymphoma.
• To identify clinical features predicting treatment response and disease-free survival.

Main Methods:

• A single-institute study treated 51 patients with intermediate- and high-grade lymphoma using the MACOP-B regimen.
• Patients received chemotherapy on an outpatient basis.
• Clinical features, response rates, disease-free survival, and toxicity were analyzed.

Main Results:

• Complete remission was achieved in 65% of patients.
• At 40 months follow-up, 40% of patients were alive, and 60% of complete responders were disease-free.
• Hematological toxicity occurred in 90% of patients, with 14% experiencing Grade IV toxicity. Severe mucositis affected 40%.

Conclusions:

• Outpatient administration of aggressive chemotherapy (MACOP-B) is feasible in India.
• The study failed to confirm the high response rates previously reported for the MACOP-B regimen.
• Patients with absence of B symptoms, non-bulky disease, and diffuse large cell histology showed better remission rates.